ArticlesPrimary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Introduction
Ovarian cancer is the leading cause of death from gynaecological cancer in developed countries.1 More than 75% of women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIC or IV) at diagnosis, of whom a substantial proportion are unwell and unfit and have a 5-year survival rate of less than 25%.1 Primary cytoreductive surgery followed by platinum-based chemotherapy is the mainstay of treatment for advanced disease. Although no randomised trials of primary surgery exist, observational studies consistently report that a lower postoperative tumour residuum is associated with longer survival.2, 3, 4, 5, 6, 7, 8 Achievement of optimum debulking (defined in the study period as disease <1 cm in maximum diameter at completion of surgery) can need complex and widespread surgery, and is more likely to be achieved when done by specialist gynaecological oncologists.9, 10, 11 Even so, many women treated in specialist centres will have bulky residual tumour after surgery.
An alternative treatment strategy using primary chemotherapy with delayed surgery has been developed. This strategy is based on the high response rate to platinum-based chemotherapy and many women have had rapid symptomatic improvement and reduction in tumour burden with it. The primary-chemotherapy strategy seemed to increase optimum debulking rates and reduce surgery related complications in observational studies,12, 13 but two meta-analyses of non-randomised studies produced conflicting results on the effect of delaying surgery on survival.14, 15
We designed the CHORUS trial to test the hypothesis that giving primary chemotherapy with delayed surgery could result in survival similar to primary surgery, with reduced surgical morbidity. A non-inferiority design was chosen because we judged that a reduction in surgery related morbidity without detriment to survival would justify the use of this treatment strategy in clinical practice.
Section snippets
Study design and participants
We designed this trial as an investigator-designed and led multicentre, randomised phase 3 trial that took place in the UK and New Zealand (appendix). We obtained national ethical and regulatory approvals in both countries and local approvals at each centre. Trial conduct and progress were monitored by an independent data monitoring committee and overseen by the UK Medical Research Council Clinical Trials Unit (MRC CTU) Gynaecological Cancer Trial Steering Committee. All participating centres
Results
Between March 1, 2004, and Aug 30, 2010, 552 women were recruited: 539 from 74 UK trial centres and 13 from two centres in New Zealand. Surgery was done at 64 trial centres. Two women were randomly assigned in error and withdrawn from the trial immediately after; one woman because she was unable to give informed consent to participation and the other because of an administrative error. These women were excluded from all analyses, and 550 women were therefore included in the final analyses (
Discussion
Our study (CHORUS) showed that for women with stage III or IV ovarian cancer with a high tumour burden, survival after receiving primary chemotherapy followed by surgery was not inferior compared with receiving primary surgery, and surgical morbidity and mortality were significantly reduced (panel).
The median survival of 22–24 months was less than expected, but was similar in both groups. The explanation for the less-than-expected overall survival might be attributed to the older median age of
References (33)
- et al.
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review
Gynecol Oncol
(2009) - et al.
Primary surgery for ovarian cancer
Eur J Surg Oncol
(2006) - et al.
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
Gynecol Oncol
(2007) - et al.
Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients
Gynecol Oncol
(1998) - et al.
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis
Gynecol Oncol
(2006) Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30
Eur J Cancer
(2001)- et al.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Lancet Oncol
(2014) - et al.
Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review
Gynecol Oncol
(2009) Cancer stats report–ovarian cancer
- et al.
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
J Clin Oncol
(2002)
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Cancer
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
Natl Cancer Inst Monogr
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data
Int J Gynecol Cancer
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
N Engl J Med
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
J Clin Oncol
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
J Clin Oncol
Cited by (1020)
Determination of quality of life-related health utilities for surgical complications in ovarian cancer
2024, Gynecologic OncologyNon-surgical management of advanced ovarian cancer with maintenance PARP inhibitors
2024, Gynecologic Oncology ReportsPyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment
2024, Biochimica et Biophysica Acta - Reviews on CancerThe Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer
2024, European Journal of Obstetrics and Gynecology and Reproductive Biology